During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...

First-line nivolumab plus ipilimumab was shown to be effective and well-tolerated in patients with unresectable hepatocellular carcinoma in the CheckMate 9DW study. In patients with unresectable ...

There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Ipilimumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase II drugs for Soft Tissue Sarcoma have a 26% phase ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

HCC in the Rio Grande Valley: Outcomes in a predominant Latino community. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full ...

Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy–Naïve Women With Hormone Receptor–Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial Supported in part ...

In a phase 1 trial, all 9 patients with renal cell carcinoma treated with a neoantigen-targeting personalized cancer vaccine ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...